As shown in Table 3, EXT1 and all these CpG sites were significantly associated overall survival, whereas the other clinical indicators were not, indicating that EXT1 and its CpG sites are important indicator and powerful biomarker for the prognosis of NSCLC. The gene discussed is EXT1; the disease is non-small cell lung carcinoma.